LONDON, April 14, 2014 /PRNewswire/ --
On Friday, April 11, 2014, the
NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones
Industrial Average declined 0.89% to 16,026.75, and the S&P 500
closed at 1,815.69, down 0.95%. The losses were broad based as all
the 10 sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 644.74, down 1.07%,
and the same has lost 4.46% in the last one month. Investor-Edge
has initiated coverage on the following equities: Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ:
INCY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Aastrom
Biosciences Inc. (NASDAQ: ASTM). Free technical research on ALXN,
INCY, MACK and ASTM can be downloaded upon signing up at:
http://www.investor-edge.com/1181-register
Shares in Alexion Pharmaceuticals Inc. declined 3.18% on Friday,
closing at $139.61, after oscillating
between $138.73 and $147.50. A total
of 2.47 million shares were traded, which is above its three months
average volume of 1.90 million shares. Shares in Alexion
Pharmaceuticals Inc. have lost 21.52% in the last one month, while
the same has gained 3.25% in the previous three months and 5.06% on
YTD basis. The company's stock is trading above its 200-day moving
average. Alexion Pharmaceuticals Inc.'s 50-day moving average of
$166.13 is above its 200-day moving
average of $129.62. Furthermore, the
company's stock is trading at a PE ratio of 97.81 and has a
Relative Strength Index (RSI) of 35.74. Sign up today to read free
research on ALXN at:
http://www.investor-edge.com/1181-ALXN-.pdf
Incyte Corp. Ltd's stock witnessed a trading volume of 2.62 million
shares on Friday, as compared with its three months average volume
of 2.09 million shares. The stock ended the day at $46.25, down 1.87%, after trading between
$46.10 and $49.52. Incyte Corp. Ltd's
shares have declined 29.23% in the last one month and 8.65% on YTD
basis. The stock is trading above its 200-day moving average.
Incyte Corp. Ltd's 50-day moving average of $60.69 is above its 200-day moving average of
$44.79. Additionally, the company's
shares have an RSI of 31.39. Sign up today to read free research on
INCY at:
http://www.investor-edge.com/1181-INCY-.pdf
On Friday, shares in Merrimack Pharmaceuticals Inc. fell by 3.27%
finishing the session at $4.73. The
stock recorded a trading volume of 1.07 million shares which is
below its three months average volume of 1.50 million shares. The
stock fluctuated between $4.69 and
$4.95 during the session. Shares in Merrimack
Pharmaceuticals Inc. have fallen by 15.69% in the last one month
and 11.27% on YTD basis. The stock is trading above its 200-day
moving average. Merrimack Pharmaceuticals Inc.'s 50-day moving
average of $5.18 is above its 200-day
moving average of $4.55. Moreover,
the company's shares have an RSI of 38.81. Sign up today to read
free research on MACK at:
http://www.investor-edge.com/1181-MACK-.pdf
Aastrom Biosciences Inc. shares recorded a trading volume of 0.35
million shares, as compared with its three months average volume of
0.38 million shares. The stock ended Friday's session at
$3.63, down 6.68%, and at an intraday
trading range of $3.60 and
$3.83. Aastrom Biosciences Inc.'s
shares have gone down by 9.70% in the last one month and 9.93% in
the previous three months, while the same has surged 12.38% on YTD
basis. The stock is trading below its 50-day and 200-day moving
averages. Aastrom Biosciences Inc.'s 200-day moving average of
$4.96 is above its 50-day moving
average of $3.82. Further, the
company's shares have an RSI of 43.27. Sign up today to read free
research on ASTM at:
http://www.investor-edge.com/1181-ASTM-.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Namrata
Maheshwari, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Namrata Maheshwari, CFA, has only
reviewed the information provided by Investor-edge in this article
or report according to the Procedures outlined by Investor-edge.
Investor-edge is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.investor-edge.com/
SOURCE Earnings Source